posted on 2023-05-21, 12:30authored byChiu, WH, Kovacheva, L, Ruth MusgroveRuth Musgrove, Arien-Zakay, H, Koprich, JB, Brotchie, J, Yaka, R, Ben-Zvi, D, Hanani, M, Roeper, J, Goldberg, JA
No disease-modifying therapy is currently available for Parkinson's disease (PD), the second most common neurodegenerative disease. The long nonmotor prodromal phase of PD is a window of opportunity for early detection and intervention. However, we lack the pathophysiological understanding to develop selective biomarkers and interventions. By using a mutant a-synuclein selective-overexpression mouse model of prodromal PD, we identified a cell-autonomous selective Kv4 channelopathy in dorsal motor nucleus of the vagus (DMV) neurons. This functional remodeling of intact DMV neurons leads to impaired pacemaker function in vitro and in vivo, which, in turn, reduces gastrointestinal motility, a common early symptom of prodromal PD. We identify a chain of events from a-synuclein via a biophysical dysfunction of a specific neuronal population to a clinically relevant prodromal symptom. These findings will facilitate the rational design of clinical biomarkers to identify people at risk for developing PD.
History
Publication title
Science Advances
Volume
7
Issue
11
Article number
eabd3994
Number
eabd3994
ISSN
2375-2548
Department/School
Menzies Institute for Medical Research
Publisher
American Association for the Advancement of Science (AAAS)
Place of publication
United States
Rights statement
Copyright 2021 The Authors Licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/